Altimmune (NASDAQ:ALT) CFO Purchases $16,200.00 in Stock

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) CFO Gregory Weaver bought 10,000 shares of the stock in a transaction on Friday, November 13th. The shares were bought at an average cost of $1.62 per share, with a total value of $16,200.00. Following the purchase, the chief financial officer owned 73,005 shares of the company’s stock, valued at $118,268.10. This trade represents a 15.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Altimmune Price Performance

Shares of ALT opened at $1.65 on Monday. The firm has a 50-day simple moving average of $2.58 and a two-hundred day simple moving average of $3.15. The stock has a market cap of $319.98 million, a PE ratio of -2.28 and a beta of 0.16. Altimmune, Inc. has a 1-year low of $1.58 and a 1-year high of $6.44. The company has a debt-to-equity ratio of 0.08, a current ratio of 23.93 and a quick ratio of 23.93.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). As a group, analysts forecast that Altimmune, Inc. will post -0.58 EPS for the current year.

More Altimmune News

Investors following ALT have been watching these news items:

  • Positive Sentiment: Newly published 48-week Phase 2b IMPACT results showed pemvidutide improved non-invasive measures of liver fat, inflammation, and fibrosis, alongside weight loss and generally favorable tolerability. The findings support the ongoing Phase 3 PERFORMA MASH trial, though pemvidutide remains investigational. Trial results article
  • Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
  • Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis

Institutional Trading of Altimmune

Hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC grew its holdings in shares of Altimmune by 21,755.0% in the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after purchasing an additional 8,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Altimmune during the 3rd quarter worth approximately $28,000. IPG Investment Advisors LLC acquired a new stake in Altimmune during the 3rd quarter worth approximately $29,000. Quantinno Capital Management LP acquired a new stake in Altimmune during the 1st quarter worth approximately $33,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Altimmune during the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on ALT shares. Weiss Ratings lowered Altimmune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Evercore restated an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. B. Riley Financial restated a “buy” rating on shares of Altimmune in a research report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Friday. Finally, Wall Street Zen downgraded Altimmune from a “sell” rating to a “strong sell” rating in a report on Saturday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Read Our Latest Report on Altimmune

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Featured Articles

Insider Buying and Selling by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.